

Ipamorelin + Tesamorelin

Lyophilised blend of two growth hormone secretagogues

BATCH

IP-IT-261002 This is the code printed on your vial.

APPLICABLE STRENGTHS

8 mg

99.23%

RP-HPLC

Specification $\geq 99.0\%$ for every component

ENDOTOXIN

< 0.1 EU/mg

Kinetic chromogenic LAL

STERILITY

No growth

Membrane filtration

ANALYSED

4 October 2026

Batch made 2 October 2026

Full analytical results

TESTS AND SPECIFICATIONS

Appearance

Visual inspection

SPECIFICATION White to off-white lyophilised powder

RESULT **Conforms**

STATUS **PASS**

Purity

RP-HPLC, each component separately; the figure shown is the limiting component

SPECIFICATION $\geq 99.0\%$ for every component

RESULT **99.23%**

STATUS **PASS**

Blend ratio

RP-HPLC, each component quantified against its own reference standard

SPECIFICATION Each component within $\pm 5.0\%$ of its declared share

RESULT **49.5% / 50.5%**

STATUS **PASS**

Related substances

RP-HPLC, any single impurity

SPECIFICATION $\leq 1.0\%$

RESULT **0.41%**

STATUS **PASS**

Water content

Karl Fischer titration

SPECIFICATION $\leq 8.0\%$

RESULT **3.68%**

STATUS **PASS**

pH, 1% aqueous solution

Potentiometry at 25 °C

SPECIFICATION 4.0 to 7.5

RESULT **5.7**

STATUS **PASS**

Bacterial endotoxins

Kinetic chromogenic LAL

SPECIFICATION < 1.0 EU/mg

RESULT **< 0.1 EU/mg**

STATUS **PASS**

Sterility

Membrane filtration (USP <71>)

SPECIFICATION No growth

RESULT No growth

STATUS PASS

Residual solvents

Headspace GC-FID (USP <467>)

SPECIFICATION Acetonitrile ≤ 410 ppm, methanol ≤ 3000 ppm, dichloromethane ≤ 600 ppm (ICH Q3C)

RESULT Conforms

STATUS PASS

Elemental impurities

ICP-MS (USP <232> and <233>)

SPECIFICATION Pb ≤ 5, Cd ≤ 2, As ≤ 15, Hg ≤ 3 µg/day (ICH Q3D, parenteral)

RESULT Conforms

STATUS PASS

COMPONENTS

A blend is only as pure as its weakest component, so the purity at the top of this certificate is the lowest of the figures below, never an average.

Ipamorelin

DECLARED 50.0%
SHARE

PURITY 99.75%

ION [M+H]⁺

OBSERVED M/Z 712.78

Tesamorelin


DECLARED 50.0%
SHARE

PURITY 99.23%

ION [M+5H]⁵⁺

OBSERVED M/Z 1028.01

CHROMATOGRAM



Reversed-phase trace for this batch. One dominant peak at 17.1 minutes, 99.23% of the total peak area, largest single impurity 0.41%.

STORAGE AND HANDLING

UNOPENED

2 to 8 °C, away from light

LONG TERM

–20 °C, lyophilised, for the stated shelf life

RECONSTITUTED

2 to 8 °C, use within 4 weeks; avoid repeated freeze and thaw

IN TRANSIT

Stable at ambient temperature for up to 30 days

RECONSTITUTE WITH

Bacteriostatic water

THE VIAL THIS COVERS



The label on your vial carries the same batch code as this certificate, **IP-IT-261002**, and the QR goes to the results for it. If the code on the vial is not this one, the certificate for it is on this page under earlier batches.

Sticker shown at its printed size, 40 by 20 mm.
Cap colour may vary by batch.

RELEASE

BATCH DATE

2 October 2026

ANALYSIS DATE

4 October 2026

ISSUE DATE

5 October 2026

BEST BEFORE

October 2028

RELEASED BY

Quality review, Indigo Peptides

DOCUMENT

Valid only in its original, unmodified form

Results are taken from the batch testing documentation for this exact batch, supplied with the finished vials and held on file by us. Every value above is for the batch named on this certificate and for no other.

HOLDING AN OLDER VIAL?

IP-IT-260911

PURITY 99.54%

ANALYSED 13 September 2026

If the code on your vial is one of these, it is an earlier batch of ours and these are its results. A result we have published is never removed and never recalculated.